RNA sequencing reveals transcriptional signatures of drug response and SARS-CoV-2 interaction in colorectal cancer cells.

ABSTRACT: This study explores the molecular impact of cisplatin, Actemra (tocilizumab), remdesivir, and SARS-CoV-2 infection on colorectal cancer (CRC) SW-480 cells using RNA sequencing (RNA-Seq). Differential gene expression analysis revealed treatment-specific transcriptional changes. Cisplatin led to the downregulation of genes involved in lipid metabolism and focal adhesion, while remdesivir upregulated chromatin remodeling pathways. SARS-CoV-2 infection altered cytokine signaling, particularly IL-17 and TNF-α. Principal component and hierarchical clustering analyses confirmed distinct gene expression profiles across treatments. ELISA assays validated the reduction of ACE2 and CD147 protein levels following drug treatment. MTT assays demonstrated remdesivir's cytotoxicity at high doses. These findings highlight potential drug-gene interactions and suggest that combining transcriptomic profiling with functional assays may guide personalized therapeutic strategies for CRC patients, especially those co-infected with SARS-CoV-2.

SUBMITTER: Hameed AK 

PROVIDER: S-EPMC12488652 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature